Tags

Type your tag names separated by a space and hit enter

Highlights of Studies in Cardiovascular Disease Prevention Presented at the 2020 American College of Cardiology Annual Scientific Session.
Curr Atheroscler Rep. 2020 Jun 18; 22(8):32.CA

Abstract

PURPOSE OF REVIEW

The review highlights selected studies related to cardiovascular disease (CVD) prevention that were presented at the American College of Cardiology 2020 Virtual Scientific Session (ACC.20)/World Cardiology Congress (WCC).

RECENT FINDINGS

The studies reviewed include clinical trials on the efficacy and safety of alirocumab (Study in Participants with Homozygous Familial Hypercholesterolemia [ODYSSEY HoFH]) and evinacumab in the treatment of homozygous familial hypercholesterolemia (HoFH); Evaluating the Efficacy of E-cigarettes for Smoking Cessation (E3); the use of renal denervation in the treatment of hypertension (SPYRAL HTN-OFF MED PIVOTAL); and the assessment of vericiguat in the treatment of heart failure (A Study of Vericiguat in Participants with Heart Failure with Reduce Ejection Fraction [VICTORIA]). In addition, results from the pooled analysis of phase III trials on inclisiran and secondary analysis examining eicosapentaenoic acid levels and cardiovascular outcomes from the Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial (REDUCE-IT) were included. Finally, we discuss studies examining the use of polygenic risk score with low density lipoprotein cholesterol (LDL-C) and systolic blood pressure (SBP) on lifetime cardiovascular risk. The studies presented at the ACC.20/WCC represent notable contributions in the field of CVD prevention.

Authors+Show Affiliations

Section of Cardiology, Baylor College of Medicine, Houston, TX, USA.Section of Cardiology, Baylor College of Medicine, Houston, TX, USA.Section of Cardiology, Baylor College of Medicine, Houston, TX, USA.Cardiovascular Division, Washington University School of Medicine in St. Louis, St. Louis, MO, USA.Division of Cardiology, University of Arizona College of Medicine-Phoenix, Phoenix, AZ, USA.Section of Cardiology, Baylor College of Medicine, Houston, TX, USA. virani@bcm.edu. Section of Cardiology, Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX, USA. virani@bcm.edu. Health Policy, Quality & Informatics Program, Health Services Research and Development Center for Innovations, Michael E. DeBakey Veterans Affairs Medical Center, 2002 Holcombe Boulevard, Houston, TX, 77030, USA. virani@bcm.edu.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

32556778

Citation

Jia, Xiaoming, et al. "Highlights of Studies in Cardiovascular Disease Prevention Presented at the 2020 American College of Cardiology Annual Scientific Session." Current Atherosclerosis Reports, vol. 22, no. 8, 2020, p. 32.
Jia X, Al Rifai M, Liu J, et al. Highlights of Studies in Cardiovascular Disease Prevention Presented at the 2020 American College of Cardiology Annual Scientific Session. Curr Atheroscler Rep. 2020;22(8):32.
Jia, X., Al Rifai, M., Liu, J., Agarwala, A., Gulati, M., & Virani, S. S. (2020). Highlights of Studies in Cardiovascular Disease Prevention Presented at the 2020 American College of Cardiology Annual Scientific Session. Current Atherosclerosis Reports, 22(8), 32. https://doi.org/10.1007/s11883-020-00856-6
Jia X, et al. Highlights of Studies in Cardiovascular Disease Prevention Presented at the 2020 American College of Cardiology Annual Scientific Session. Curr Atheroscler Rep. 2020 Jun 18;22(8):32. PubMed PMID: 32556778.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Highlights of Studies in Cardiovascular Disease Prevention Presented at the 2020 American College of Cardiology Annual Scientific Session. AU - Jia,Xiaoming, AU - Al Rifai,Mahmoud, AU - Liu,Jing, AU - Agarwala,Anandita, AU - Gulati,Martha, AU - Virani,Salim S, Y1 - 2020/06/18/ PY - 2020/6/20/entrez PY - 2020/6/20/pubmed PY - 2020/6/20/medline KW - ASCVD risk reduction KW - Cardiovascular disease prevention KW - Risk factor assessment SP - 32 EP - 32 JF - Current atherosclerosis reports JO - Curr Atheroscler Rep VL - 22 IS - 8 N2 - PURPOSE OF REVIEW: The review highlights selected studies related to cardiovascular disease (CVD) prevention that were presented at the American College of Cardiology 2020 Virtual Scientific Session (ACC.20)/World Cardiology Congress (WCC). RECENT FINDINGS: The studies reviewed include clinical trials on the efficacy and safety of alirocumab (Study in Participants with Homozygous Familial Hypercholesterolemia [ODYSSEY HoFH]) and evinacumab in the treatment of homozygous familial hypercholesterolemia (HoFH); Evaluating the Efficacy of E-cigarettes for Smoking Cessation (E3); the use of renal denervation in the treatment of hypertension (SPYRAL HTN-OFF MED PIVOTAL); and the assessment of vericiguat in the treatment of heart failure (A Study of Vericiguat in Participants with Heart Failure with Reduce Ejection Fraction [VICTORIA]). In addition, results from the pooled analysis of phase III trials on inclisiran and secondary analysis examining eicosapentaenoic acid levels and cardiovascular outcomes from the Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial (REDUCE-IT) were included. Finally, we discuss studies examining the use of polygenic risk score with low density lipoprotein cholesterol (LDL-C) and systolic blood pressure (SBP) on lifetime cardiovascular risk. The studies presented at the ACC.20/WCC represent notable contributions in the field of CVD prevention. SN - 1534-6242 UR - https://www.unboundmedicine.com/medline/citation/32556778/Highlights_of_Studies_in_Cardiovascular_Disease_Prevention_Presented_at_the_2020_American_College_of_Cardiology_Annual_Scientific_Session L2 - https://dx.doi.org/10.1007/s11883-020-00856-6 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.